SABS vs. CRIS, SGMO, AGEN, OKYO, NKGN, DYAI, ESLA, CDTX, BCLI, and QNCX
Should you be buying SAB Biotherapeutics stock or one of its competitors? The main competitors of SAB Biotherapeutics include Curis (CRIS), Sangamo Therapeutics (SGMO), Agenus (AGEN), OKYO Pharma (OKYO), NKGen Biotech (NKGN), Dyadic International (DYAI), Estrella Immunopharma (ESLA), Cidara Therapeutics (CDTX), Brainstorm Cell Therapeutics (BCLI), and Quince Therapeutics (QNCX). These companies are all part of the "biological products, except diagnostic" industry.
Curis (NASDAQ:CRIS) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.
Curis received 667 more outperform votes than SAB Biotherapeutics when rated by MarketBeat users. However, 73.91% of users gave SAB Biotherapeutics an outperform vote while only 67.52% of users gave Curis an outperform vote.
30.0% of Curis shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 5.7% of Curis shares are owned by company insiders. Comparatively, 26.0% of SAB Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Curis has a net margin of -473.04% compared to Curis' net margin of -1,884.10%. Curis' return on equity of -144.66% beat SAB Biotherapeutics' return on equity.
SAB Biotherapeutics has lower revenue, but higher earnings than Curis.
Curis currently has a consensus price target of $37.33, suggesting a potential upside of 128.20%. SAB Biotherapeutics has a consensus price target of $15.50, suggesting a potential upside of 284.62%. Given Curis' higher possible upside, analysts plainly believe SAB Biotherapeutics is more favorable than Curis.
Curis has a beta of 3.59, meaning that its share price is 259% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500.
In the previous week, Curis had 2 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 2 mentions for Curis and 0 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 0.00 equaled Curis'average media sentiment score.
Summary
Curis beats SAB Biotherapeutics on 9 of the 15 factors compared between the two stocks.
Get SAB Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SAB Biotherapeutics Competitors List
Related Companies and Tools
